Works by Strober, Bruce


Results: 88
    1
    2
    3
    4
    5
    6
    7

    Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2025, v. 39, n. 7, p. 1336, doi. 10.1111/jdv.20553
    By:
    • Armstrong, April W.;
    • Lebwohl, Mark;
    • Warren, Richard B.;
    • Sofen, Howard;
    • Morita, Akimichi;
    • Paul, Carle;
    • Papp, Kim A.;
    • Colombo, Matthew J.;
    • Scotto, Julie;
    • Vaile, John;
    • Zhuo, Joe;
    • Vritzali, Eleni;
    • Berger, Victoria;
    • Schroeder, Georgene;
    • Banerjee, Subhashis;
    • Thaçi, Diamant;
    • Strober, Bruce
    Publication type:
    Article
    8

    Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
    By:
    • Strober, Bruce;
    • Blauvelt, Andrew;
    • Warren, Richard B.;
    • Papp, Kim A.;
    • Armstrong, April W.;
    • Gordon, Kenneth B.;
    • Morita, Akimichi;
    • Alexis, Andrew F.;
    • Lebwohl, Mark;
    • Foley, Peter;
    • Kisa, Renata M.;
    • Colston, Elizabeth;
    • Wang, Tao;
    • Banerjee, Subhashis;
    • Thaçi, Diamant
    Publication type:
    Article
    9

    Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 5, p. 864, doi. 10.1111/jdv.19748
    By:
    • Strober, Bruce;
    • Bachelez, Hervé;
    • Crowley, Jeffrey;
    • Elewski, Boni E.;
    • Gooderham, Melinda;
    • Menter, Alan;
    • Strohal, Robert;
    • Chen, Michael M.;
    • Wu, Tianshuang;
    • Zhan, Tianyu;
    • Photowala, Huzefa;
    • Armstrong, April
    Publication type:
    Article
    10

    Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 10, p. 2056, doi. 10.1111/jdv.19280
    By:
    • Reich, Kristian;
    • Silverberg, Jonathan I.;
    • Papp, Kim A.;
    • Deleuran, Mette;
    • Katoh, Norito;
    • Strober, Bruce;
    • Beck, Lisa A.;
    • de Bruin‐Weller, Marjolein;
    • Werfel, Thomas;
    • Zhang, Fan;
    • Biswas, Pinaki;
    • DiBonaventura, Marco D.;
    • Chan, Gary;
    • Johnson, Susan;
    • Farooqui, Saleem A.;
    • Kerkmann, Urs;
    • Clibborn, Claire
    Publication type:
    Article
    11
    12

    Pharmacology of orismilast, a potent and selective PDE4 inhibitor.

    Published in:
    Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 4, p. 721, doi. 10.1111/jdv.18818
    By:
    • Silverberg, Jonathan I.;
    • French, Lars E.;
    • Warren, Richard B.;
    • Strober, Bruce;
    • Kjøller, Kim;
    • Sommer, Morten O. A.;
    • Andres, Philippe;
    • Felding, Jakob;
    • Weiss, Anne;
    • Tutkunkardas, Deniz;
    • Skak-Nielsen, Tine;
    • Guttman, Emma
    Publication type:
    Article
    13
    14

    Management of Challenging Psoriasis Clinical Scenarios.

    Published in:
    Dermatology & Therapy, 2025, v. 15, n. 6, p. 1555, doi. 10.1007/s13555-025-01393-3
    By:
    • Stein Gold, Linda;
    • Alexis, Andrew;
    • Glick, Brad P.;
    • Shahriari, Mona;
    • Song, Eingun James;
    • Strober, Bruce;
    • Watch, Najat M.;
    • Young, Melodie
    Publication type:
    Article
    15
    16

    Brodalumab: Six-Year US Pharmacovigilance Report.

    Published in:
    Dermatology & Therapy, 2025, v. 15, n. 1, p. 213, doi. 10.1007/s13555-024-01304-y
    By:
    • Lebwohl, Mark G.;
    • Koo, John Y.;
    • Armstrong, April W.;
    • Strober, Bruce E.;
    • Yoon, Soo Han;
    • Rawnsley, Nicole N.;
    • Goehring Jr, Earl L.;
    • Mangin, Gina D.;
    • Jacobson, Abby A.
    Publication type:
    Article
    17
    18

    Brodalumab: 5-Year US Pharmacovigilance Report.

    Published in:
    Dermatology & Therapy, 2024, v. 14, n. 5, p. 1349, doi. 10.1007/s13555-024-01162-8
    By:
    • Lebwohl, Mark G.;
    • Koo, John Y.;
    • Armstrong, April W.;
    • Strober, Bruce E.;
    • Martin, George M.;
    • Rawnsley, Nicole N.;
    • Goehring Jr., Earl L.;
    • Jacobson, Abby A.
    Publication type:
    Article
    19
    20
    21
    22

    Unmet Educational Needs and Clinical Practice Gaps in the Management of Generalized Pustular Psoriasis: Global Perspectives from the Front Line.

    Published in:
    Dermatology & Therapy, 2022, v. 12, n. 2, p. 381, doi. 10.1007/s13555-021-00661-2
    By:
    • Strober, Bruce;
    • Leman, Joyce;
    • Mockenhaupt, Maja;
    • Nakano de Melo, Juliana;
    • Nassar, Ahmed;
    • Prajapati, Vimal H.;
    • Romanelli, Paolo;
    • Seneschal, Julien;
    • Tsianakas, Athanasios;
    • Wei, Lee Yoong;
    • Yasuda, Masahito;
    • Yu, Ning;
    • Hernandez Daly, Ana C.;
    • Okubo, Yukari
    Publication type:
    Article
    23

    Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

    Published in:
    Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
    By:
    • Thaçi, Diamant;
    • Strober, Bruce;
    • Gordon, Kenneth B.;
    • Foley, Peter;
    • Gooderham, Melinda;
    • Morita, Akimichi;
    • Papp, Kim A.;
    • Puig, Lluís;
    • Menter, M. Alan;
    • Colombo, Matthew J.;
    • Elbez, Yedid;
    • Kisa, Renata M.;
    • Ye, June;
    • Napoli, Andrew A.;
    • Wei, Lan;
    • Banerjee, Subhashis;
    • Merola, Joseph F.;
    • Gottlieb, Alice B.
    Publication type:
    Article
    24
    25
    26
    27

    Clinical Goals and Barriers to Effective Psoriasis Care.

    Published in:
    Dermatology & Therapy, 2019, v. 9, n. 1, p. 5, doi. 10.1007/s13555-018-0279-5
    By:
    • Strober, Bruce E.;
    • van der Walt, Joelle M.;
    • Armstrong, April W.;
    • Bourcier, Marc;
    • Carvalho, Andre V. E.;
    • Chouela, Edgardo;
    • Cohen, Arnon D.;
    • de la Cruz, Claudia;
    • Ellis, Charles N.;
    • Finlay, Andrew Y.;
    • Gottlieb, Alice B.;
    • Gudjonsson, Johann E.;
    • Iversen, Lars;
    • Kleyn, C. Elise;
    • Leonardi, Craig L.;
    • Lynde, Charles W.;
    • Ryan, Caitriona;
    • Theng, Colin T.;
    • Valenzuela, Fernando;
    • Vender, Ronald
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36

    Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab.

    Published in:
    Journal of Dermatological Treatment, 2017, v. 28, n. 6, p. 492, doi. 10.1080/09546634.2017.1294727
    By:
    • Elewski, Boni E.;
    • Puig, Lluís;
    • Mordin, Margaret;
    • Gilloteau, Isabelle;
    • Sherif, Bintu;
    • Fox, Todd;
    • Gnanasakthy, Ari;
    • Papavassilis, Charis;
    • Strober, Bruce E.
    Publication type:
    Article
    37
    38
    39
    40

    Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

    Published in:
    2013
    By:
    • Lessin, Stuart R;
    • Duvic, Madeleine;
    • Guitart, Joan;
    • Pandya, Amit G;
    • Strober, Bruce E;
    • Olsen, Elise A;
    • Hull, Christopher M;
    • Knobler, Elizabeth H;
    • Rook, Alain H;
    • Kim, Ellen J;
    • Naylor, Mark F;
    • Adelson, David M;
    • Kimball, Alexa B;
    • Wood, Gary S;
    • Sundram, Uma;
    • Wu, Hong;
    • Kim, Youn H
    Publication type:
    journal article
    41

    Topical Chemotherapy in Cutaneous T-cell Lymphoma.

    Published in:
    JAMA Dermatology, 2013, v. 149, n. 1, p. 25, doi. 10.1001/2013.jamadermatol.541
    By:
    • Lessin, Stuart R.;
    • Duvic, Madeleine;
    • Guitart, Joan;
    • Pandya, Amit G.;
    • Strober, Bruce E.;
    • Olsen, Elise A.;
    • Hull, Christopher M.;
    • Knobler, Elizabeth H.;
    • Rook, Alain H.;
    • Kim, Ellen J.;
    • Naylor, Mark F.;
    • Adelson, David M.;
    • Kimball, Alexa B.;
    • Wood, Gary S.;
    • Sundram, Uma;
    • Hong Wu;
    • Youn H. Kim
    Publication type:
    Article
    42

    Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.

    Published in:
    Journal of Dermatological Treatment, 2024, v. 35, n. 1, p. 1, doi. 10.1080/09546634.2024.2371045
    By:
    • Korman, Neil J.;
    • Warren, Richard B.;
    • Bagel, Jerry;
    • Armstrong, April W.;
    • Gooderham, Melinda;
    • Strober, Bruce;
    • Thaçi, Diamant;
    • Morita, Akimichi;
    • Imafuku, Shinichi;
    • Foley, Peter;
    • Sofen, Howard;
    • Zheng, Min;
    • Hippeli, Lauren;
    • Kisa, Renata M.;
    • Banerjee, Subhashis;
    • Blauvelt, Andrew
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49

    Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials.

    Published in:
    JAMA: Journal of the American Medical Association, 2011, v. 306, n. 8, p. 864, doi. 10.1001/jama.2011.1211
    By:
    • Ryan, Caitriona;
    • Leonardi, Craig L.;
    • Krueger, James G.;
    • Kimball, Alexa B.;
    • Strober, Bruce E.;
    • Gordon, Kenneth B.;
    • Langley, Richard G.;
    • de Lemos, James A.;
    • Daoud, Yahya;
    • Blankenship, Derek;
    • Kazi, Salahuddin;
    • Kaplan, Dan H.;
    • Friedewald, Vincent E.;
    • Menter, Alan
    Publication type:
    Article
    50